Instituto Global para la Excelencia en el Cuidado de la Salud Keralty2026-04-102026-04-102022https://repositorio.unisanitas.edu.co/handle/123456789/1163COVID-19 antiviral treatments are still in the early stages of development, considering that the disease was first identified in late 2019. The cost of molnupiravir estimated from the U.S. government's published purchase price is $700 per 5-day treatment (Willyard, 2021). The molnupiravir (lagevrio) mechanism has a high potential for long-term risk. This antiviral works by incorporating itself into viral RNA, creating errors, and preventing effective replication within days (Kabinger et al., 2021). Introducing/provoking mutations in a virus can lead to potentially dangerous changes, especially when poor adherence or total drug consumption cannot be guaranteed. Also, laboratory results showed a low frequency of mutations in human DNA in blood cells and spermatozoa. Its mechanism of action and the observed effects make its use unfeasible during pregnancy. The evidence collected by Bernal et al. had a high risk of bias in the outcomes evaluated for its effectiveness (incidence of hospitalization for any cause (defined as ≥24 hours of acute care in a hospital or any similar center or death up to day 29). Therefore, the recommendation for using Molnupiravir should be evaluated with caution, given that there is little evidence regarding its effectiveness and safety. Additionally, the only peer-reviewed study presents a low level of certainty of the evidence, and the risks appear to be higher than the potential benefits.textenDocumento